4D Molecular Therapeutics (NASDAQ:FDMT) Posts Earnings Results, Misses Expectations By $0.02 EPS

4D Molecular Therapeutics (NASDAQ:FDMT) posted its quarterly earnings results on Thursday. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02), FiscalAI reports. 4D Molecular Therapeutics had a negative return on equity of 40.52% and a negative net margin of 194.74%.The company had revenue of $3.78 million for the quarter, compared to analyst estimates of $3.62 million.

4D Molecular Therapeutics Stock Up 4.6%

NASDAQ FDMT opened at $12.19 on Friday. The stock has a market capitalization of $637.29 million, a PE ratio of -4.63 and a beta of 2.73. 4D Molecular Therapeutics has a 12-month low of $5.97 and a 12-month high of $14.00. The company has a 50 day moving average price of $10.94 and a two-hundred day moving average price of $9.87.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. The Goldman Sachs Group restated a “buy” rating and set a $32.00 price target on shares of 4D Molecular Therapeutics in a report on Thursday. Wall Street Zen downgraded shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Chardan Capital upgraded 4D Molecular Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. Finally, HC Wainwright reissued a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, 4D Molecular Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $29.62.

Insiders Place Their Bets

In other news, insider Scott Bizily sold 9,810 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $12.00, for a total transaction of $117,720.00. Following the transaction, the insider owned 8,617 shares in the company, valued at approximately $103,404. This trade represents a 53.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David Kirn sold 114,746 shares of the stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $10.47, for a total transaction of $1,201,390.62. Following the transaction, the insider directly owned 942,485 shares in the company, valued at $9,867,817.95. The trade was a 10.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 197,226 shares of company stock worth $2,200,677 in the last 90 days. 7.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in FDMT. Wexford Capital LP bought a new stake in 4D Molecular Therapeutics during the third quarter worth approximately $41,000. Daiwa Securities Group Inc. raised its position in shares of 4D Molecular Therapeutics by 3,362.0% in the fourth quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock valued at $48,000 after purchasing an additional 6,186 shares during the period. Susquehanna Portfolio Strategies LLC bought a new position in shares of 4D Molecular Therapeutics in the fourth quarter valued at approximately $77,000. Martingale Asset Management L P lifted its stake in shares of 4D Molecular Therapeutics by 12.4% in the fourth quarter. Martingale Asset Management L P now owns 11,775 shares of the company’s stock worth $88,000 after buying an additional 1,303 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of 4D Molecular Therapeutics during the 1st quarter worth $39,000. 99.27% of the stock is owned by institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.